Sublingual GLP-1 (RDT)

Sublingual GLP-1 Rapid-Dissolve Tablets (RDTs) are compounded tablets designed to dissolve quickly under the tongue, allowing active pharmaceutical ingredients — semaglutide or tirzepatide — to be absorbed through the sublingual mucosa. This delivery format offers a needle-free pathway to GLP-1-based weight management therapy for patients who are not candidates for or prefer to avoid injectable formulations.

Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. Both mechanisms engage incretin pathways to support glucose-dependent insulin release, suppress appetite-driving glucagon secretion, and slow the rate at which the stomach empties. Tirzepatide's additional GIP receptor activity represents a distinct pharmacological profile that your provider may consider when selecting the appropriate active ingredient for your clinical situation.

Dosing follows a structured titration protocol, typically starting at a lower dose and increasing at defined intervals to support tolerability. Available in a range of concentrations from 1 mg to 12 mg, the formulation can be adjusted to match your stage of therapy and your provider's clinical judgment. All prescriptions are issued only after a licensed provider has reviewed your health history through a comprehensive online medical consultation.

RDTs may be suitable for adults with a BMI indicating overweight or obesity who are committed to dietary and lifestyle changes alongside pharmacotherapy. They are not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN2. As with all GLP-1 and GIP/GLP-1 medications, common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose increases. These are typically manageable and often lessen with time. These are compounded medications prepared by a licensed 503A pharmacy and are not FDA-approved drug products in this format.